Trial · NCT05649579
Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
NCT05649579, Completed, Peking University First Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid. Trials, record NCT05649579. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05649579
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
- NCT number
- NCT05649579
- Status
- Completed
- Enrollment
- 146 participants, actual
- Lead sponsor
- Peking University First Hospital
- Conditions
- Bullous Pemphigoid
- Interventions
- Dupilumab
- First posted
- 2022-12-14
- Last updated
- 2023-12-04
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients reached disease control | within 4 weeks | Disease control was defined as the point at which new lesions or pruritic symptoms cease to form and existing lesions start to heal. |
| Secondary | Complete remission rate | within 64 weeks | Complete remission is defined as the absence of new or established lesions or pruritus while the patient is receiving minimal therapy or off therapy for at least 2 months. |
| Secondary | Relapse rate | within 64 weeks | Relapse was defined as the appearance of three or more new lesions a month or at least one eczematous lesion with a diameter \>10cm or urticarial plaque that does not heal within one week, or the extension of established lesions or daily pruritus in a patient who has achieved disease control. |
| Secondary | Adverse events | within 64 weeks | Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. |
| Secondary | Changes in BPDAI scores | from 0 to 64 weeks | Disease severity was assessed using the bullous pemphigoid disease area index (BPDAI) score and was classified into mild (BPDAI≤19), moderate (20≤BPDAI≤56), and severe (BPDAI≥57). |
| Secondary | Changes in itching NRS scores | from 0 to 64 weeks | Pruritus was evaluated via itching numeric rating scale (NRS), ranging from 0 (no itch) to 10 points (worst imaginable itch). |
| Secondary | Changes in serum anti-BP180 antibodies | from 0 to 64 weeks | |
| Secondary | Changes in serum anti-BP230 antibodies | from 0 to 64 weeks | |
| Secondary | Changes in serum total IgE | from 0 to 64 weeks | |
| Secondary | Changes in peripheral blood eosinophil count | from 0 to 64 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05649579
GET https://conductscience.org/api/trials/v1/NCT05649579/registered